Table 3.

The pharmacokinetic parameters of plasma DBZ and DSS

Drug	Parameter	Unit	DBZ	DBZ-NLC	DBZ-PEG-NLC
DBZ	AUC0–∞	mg/L h	0.392±0.043	0.869±0.107a	2.291±0.334a,b
	Vd	L/kg	3.387±0.463	3.557±0.415	4.209±0.486
	CL	L/h kg	16.141±2.135	6.903±0.882a	2.512±0.201a,b
	MRT0–∞	H	0.149±0.015	0.316±0.043a	1.301±0.152a,b
DSS	AUC0–∞	mg/L h	0.403±0.041	0.938±0.131a	2.266±0.218a,b
	Vd	L/kg	6.498±0.918	5.395±0.735	5.389±0.885
	CL	L/h kg	14.658±2.514	6.405±0.798a	2.606±0.276a,b
	MRT0–∞	H	0.305±0.045	0.516±0.067a	1.749±0.239a,b

Notes: Data are expressed as the mean ± SD of each group (n=6) from three separate experiments following intravenous administration of DBZ, DBZ-NLC, or DBZ-PEG- NLC at a dose of 6 mg/kg.

^ap<0.05 vs the DBZ;

^bp<0.05 vs the DBZ-NLC.

Abbreviations: AUC, area under the plasma concentration–time curve; CL, clearance; DBZ, tanshinol borneol ester; DBZ-NLC, DBZ nanostructured lipid carriers; DBZ-PEG-NLC, polyethylene glycol (PEG)-modified and DBZ-loaded nanostructured lipid carriers; DSS, danshensu; MRT_0–∞, mean residency time; V_d, volume of body distribution.